Identification | Back Directory | [Name]
AZD-5069 | [CAS]
878385-84-3 | [Synonyms]
CS-2808 AZD-5069 CPDD1543 ACT-281959 AZD 5069; AZD5069 AZD-5069; AZD 5069; AZD5069;878385-84-3 N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide 1-Azetidinesulfonamide, N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R,2S)-2,3-dihydroxy-1-methylpropoxy]-4-pyrimidinyl]- | [Molecular Formula]
C18H22F2N4O5S2 | [MDL Number]
MFCD31631376 | [MOL File]
878385-84-3.mol | [Molecular Weight]
476.52 |
Chemical Properties | Back Directory | [Melting point ]
149-152°C | [Boiling point ]
680.5±65.0 °C(Predicted) | [density ]
1.56±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
4.56±0.20(Predicted) | [color ]
White to Off-White |
Hazard Information | Back Directory | [Description]
AZD5069 is a potent, selective reversible (time and temperature dependent) antagonist of the human CXCR2 receptor that used for caner treatment. | [Uses]
AZD-5069 is a potent and selective CXCR2 antagonist with potential as a therapeutic agent in inflammatory conditions. | [Biological Activity]
AZD 5069 is an antagonist of chemokine receptor 2 (CXCR2; IC50 = 0.79 nM in a radioligand binding assay). It inhibits CXCL1-induced CD11b expression in and chemotaxis of isolated human neutrophils (pA2s = 6.9 and 9.1, respectively). AZD 5069 (3 and 10 μmol/kg) inhibits bronchoalveolar lavage fluid (BALF) neutrophil influx in a rat model of LPS-induced lung neutrophilia and non-allergic airway inflammation. |
|
|